These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 33574091)

  • 1. Inflammation and Apolipoproteins Are Potential Biomarkers for Stratification of Cutaneous Melanoma Patients for Immunotherapy and Targeted Therapy.
    Karlsson MJ; Costa Svedman F; Tebani A; Kotol D; Höiom V; Fagerberg L; Edfors F; Uhlén M; Egyhazi Brage S; Maddalo G
    Cancer Res; 2021 May; 81(9):2545-2555. PubMed ID: 33574091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma.
    Babačić H; Lehtiö J; Pico de Coaña Y; Pernemalm M; Eriksson H
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition.
    Laino AS; Woods D; Vassallo M; Qian X; Tang H; Wind-Rotolo M; Weber J
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. uPAR
    Porcelli L; Guida M; De Summa S; Di Fonte R; De Risi I; Garofoli M; Caputo M; Negri A; Strippoli S; Serratì S; Azzariti A
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33972390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy.
    Turiello R; Capone M; Giannarelli D; Morretta E; Monti MC; Madonna G; Mallardo D; Festino L; Azzaro R; Levesque MP; Imhof L; Weide B; Amaral T; Chevrier M; Sucker A; Rutkowski P; Schadendorf D; Lebbe C; Luke JJ; Wistuba-Hamprecht K; Dummer R; Pinto A; Morello S; Ascierto PA
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33361405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
    Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
    Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?
    Schummer P; Schilling B; Gesierich A
    Am J Clin Dermatol; 2020 Aug; 21(4):493-504. PubMed ID: 32124332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy in melanoma: Can we predict response to treatment with circulating biomarkers?
    Splendiani E; Besharat ZM; Covre A; Maio M; Di Giacomo AM; Ferretti E
    Pharmacol Ther; 2024 Apr; 256():108613. PubMed ID: 38367867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.
    Jiang J; Ding Y; Wu M; Chen Y; Lyu X; Lu J; Wang H; Teng L
    Cancer Med; 2020 Nov; 9(22):8498-8518. PubMed ID: 32969604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-reactive protein flare predicts response to checkpoint inhibitor treatment in melanoma.
    Kött J; Zimmermann N; Zell T; Heidrich I; Geidel G; Rünger A; Smit DJ; Merkle M; Parnian N; Hansen I; Hoehne I; Abeck F; Torster L; Weichenthal M; Pantel K; Schneider SW; Gebhardt C
    J Eur Acad Dermatol Venereol; 2024 Aug; 38(8):1575-1587. PubMed ID: 38466133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma.
    Krebs FK; Trzeciak ER; Zimmer S; Özistanbullu D; Mitzel-Rink H; Meissner M; Grabbe S; Loquai C; Tuettenberg A
    Cancer Med; 2021 Mar; 10(5):1562-1575. PubMed ID: 33449393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma.
    Kubo Y; Fukushima S; Inamori Y; Tsuruta M; Egashira S; Yamada-Kanazawa S; Nakahara S; Tokuzumi A; Miyashita A; Aoi J; Kajihara I; Tomita Y; Wakamatsu K; Jinnin M; Ihn H
    J Dermatol Sci; 2019 Jan; 93(1):33-40. PubMed ID: 30318169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential predictive value of SCN4A mutation status for immune checkpoint inhibitors in melanoma.
    Lin W; Lin A; Li Z; Zhou C; Chen C; Chen B; Lyu Q; Zhang J; Luo P
    Biomed Pharmacother; 2020 Nov; 131():110633. PubMed ID: 32892029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF-mutant advanced melanoma treated with first-line anti-PD-1 monotherapies or BRAF/MEK inhibitors in a community-based oncology setting.
    Cowey CL; Boyd M; Aguilar KM; Beeks A; Krepler C; Scherrer E
    Cancer Med; 2020 Nov; 9(21):7863-7878. PubMed ID: 32871054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of Resistance to BRAF-Targeted Melanoma Therapies.
    Dulgar O; Kutuk T; Eroglu Z
    Am J Clin Dermatol; 2021 Jan; 22(1):1-10. PubMed ID: 33368052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma.
    Franzke A; Probst-Kepper M; Buer J; Duensing S; Hoffmann R; Wittke F; Volkenandt M; Ganser A; Atzpodien J
    Br J Cancer; 1998 Jul; 78(1):40-5. PubMed ID: 9662248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.
    Gupta S; McCann L; Chan YGY; Lai EW; Wei W; Wong PF; Smithy JW; Weidler J; Rhees B; Bates M; Kluger HM; Rimm DL
    J Immunother Cancer; 2019 Sep; 7(1):254. PubMed ID: 31533832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma.
    Hoffmann F; Zarbl R; Niebel D; Sirokay J; Fröhlich A; Posch C; Holderried TAW; Brossart P; Saavedra G; Kuster P; Strieth S; Gielen GH; Ring SS; Dietrich J; Pietsch T; Flatz L; Kristiansen G; Landsberg J; Dietrich D
    Clin Epigenetics; 2020 Jun; 12(1):94. PubMed ID: 32586358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.
    Menzies AM; Wilmott JS; Drummond M; Lo S; Lyle M; Chan MM; Thompson JF; Guminski A; Carlino MS; Scolyer RA; Kefford RF; Long GV
    Cancer; 2015 Nov; 121(21):3826-35. PubMed ID: 26218930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.